Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Allogene Therapeutics Inc shares valued at $683 were purchased by Parker Geoffrey M. on Jan 30 ’24. At $3.60 per share, Parker Geoffrey M. acquired 190 shares. The insider’s holdings grew to 819,590 shares worth approximately $3.27 million following the completion of this transaction.
Also, MESSEMER DEBORAH M. sold 18,640 shares, netting a total of over 50,317 in proceeds. Following the sale of shares at $2.70 each, the insider now holds 62,456 shares.
Before that, Mayo Stephen had sold 10,000 shares from its account. In a trade valued at $42,855, the Director traded Allogene Therapeutics Inc shares for $4.29 each. Upon closing the transaction, the insider’s holdings decreased to 10,000 shares, worth approximately $0.1 million.
As published in a research note from JMP Securities on January 05, 2024, Allogene Therapeutics Inc [ALLO] has been rated down from a Mkt outperform to a Mkt perform. Analysts at Guggenheim downgraded the stock from ‘”a Buy”‘ to ‘”a Neutral”‘ outlook in a report released in early January. As of December 08, 2023, Citigroup has initiated its “Buy” rating for ALLO. Earlier on December 08, 2023, Citigroup initiated its rating. Their recommendation was “a Buy” for ALLO stock.
Analyzing ALLO Stock Performance
During the last five days, there has been a drop of approximately -1.48%. Over the course of the year, Allogene Therapeutics Inc shares have jumped approximately 24.30%. Shares of the company reached a 52-week high of $5.78 on 03/08/24 and a 52-week low of $2.61 on 01/05/24. A 50-day SMA is recorded $4.53, while a 200-day SMA reached $3.82. Nevertheless, trading volume fell to 2.15 million shares from 1.37 million shares the previous day.
Support And Resistance Levels for Allogene Therapeutics Inc (ALLO)
According to the 24-hour chart, there is a support level at 3.92, which, if violated, would cause prices to drop to 3.84. In the upper region, resistance lies at 4.14. The next price resistance is at 4.28. RSI (Relative Strength Index) is 39.86 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.11, which suggests the price will decrease in the coming days. Percent R is at 84.21%, indicating bearish price movement. Stochastics %K at holding indicates that the stock is to be held.
Is Allogene Therapeutics Inc subject to short interest?
Stocks of Allogene Therapeutics Inc saw a sharp rise in short interest on Mar 15, 2024 jumping by 4.3 million shares to 27.75 million. Data from Yahoo Finance shows that the short interest on Feb 15, 2024 was 23.45 million shares. A jump of 15.5% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 10.12 of the overall float, the days-to-cover ratio (short ratio) jumped to 10.12.
